Hong Kong stock anomaly | Concept stocks of innovative drugs are under pressure, liquidity tightening directly suppresses sector valuations, institutions point out that the impact of the BINSA draft is biased towards sentiment.

According to the Zhitong Finance APP, concept stocks of innovative drugs are under pressure across the board. As of the time of publication, Shinda Biopharmaceuticals (01801.HK) fell by 4.9% to 72.85 Hong Kong dollars; Sansheng Pharmaceuticals (01530.HK) fell by 3.44% to 15.14 Hong Kong dollars; Zhongsheng Pharmaceuticals (01177.HK) fell by 3% to 4.52 Hong Kong dollars; and CSPC Pharmaceutical Group (01093) fell by 2.49% to 7.06 Hong Kong dollars.